Basecare Wins First China Approval for Thalassemia-Focused PGT-M Kit, Strengthening IVF Genetics Lead

Suzhou Basecare Medical Corp. Ltd. Class H ( (HK:2170) ) just unveiled an update.

Suzhou Basecare Medical Corporation Limited has received national Class III medical device registration from Chinese regulators for its independently developed Pre-implantation Genetic Testing Kit for Thalassemia, becoming the first such thalassemia-focused PGT-M kit approved for market launch in China. The kit qualitatively detects genomic DNA from embryos and parents to identify inherited pathogenic variants, helping clinicians select embryos that are free of severe thalassemia, a condition affecting millions of carriers in China and driving high birth-defect risk in southern regions.

As the first domestically developed PGT-M product specifically targeting familial thalassemia prevention, the new kit fills a key gap in China’s home-grown pre-implantation testing market and supports a major national R&D initiative on reproductive health under the 14th Five-Year Plan. The approval broadens Basecare’s PGT portfolio, is expected to boost revenue in its genetic laboratory business, and further consolidates its leadership in third-generation IVF genetic testing, while also enhancing China’s broader birth-defect prevention and control capabilities for thalassemia.

The launch comes as health authorities intensify programs to standardize diagnosis and treatment of priority birth-defect conditions, including thalassemia, and to expand access to precise pre-conception genetic tools. By enabling families with thalassemia gene carriers to avoid transmitting the disease to the next generation, the product is anticipated to deliver both public health benefits and strategic commercial advantages for Basecare in the fast-growing reproductive genetics market.

More about Suzhou Basecare Medical Corp. Ltd. Class H

Suzhou Basecare Medical Corporation Limited is a China-based medical device company specializing in genetic testing solutions for in vitro fertilization (IVF). The group focuses on pre-implantation genetic testing (PGT) products, including PGT-A, PGT-M and PGT-SR kits, and holds more than 50% share of the PGT-compliant market in China through partnerships with around 300 hospitals and over 60 joint laboratories.

The company has built deep collaborations with more than 80 leading third-generation reproductive centers across the country. Its product portfolio is positioned to support reproductive health and birth-defect prevention, aligning with national initiatives to improve women’s and children’s health protection and strengthen genetic screening capabilities in assisted reproduction.

Average Trading Volume: 126,421

Technical Sentiment Signal: Sell

Current Market Cap: HK$519.7M

See more data about 2170 stock on TipRanks’ Stock Analysis page.